Last reviewed · How we verify
Picato — Competitive Intelligence Brief
discontinued
Protein kinase C alpha type, Protein kinase C epsilon type, Protein kinase C gamma type
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Picato (Picato) — LEO Pharma.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Picato TARGET | Picato | LEO Pharma | discontinued | Protein kinase C alpha type, Protein kinase C epsilon type, Protein kinase C gamma type | ||
| Picato | INGENOL MEBUTATE | Leo Labs | marketed | Protein kinase C alpha type, Protein kinase C epsilon type, Protein kinase C gamma type | 2012-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Picato — Competitive Intelligence Brief. https://druglandscape.com/ci/picato. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab